# US 2023/0053437 A1 · Lipid compounds and lipid nanoparticle compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053437 A1
- Document ID: US20230053437A1
- Status: Published application
- Kind: A1
- Application number: 17/785,315
- Filed: 2021-08-19
- Published: 2023-02-23
- Earliest claimed: 2020-08-20
- Assignees: Suzhou Abogen Biosciences Co., Ltd.
- Applicants: Suzhou Abogen Biosciences Co., Ltd.
- Inventors: Bo Ying
- Web page: https://patentgrep.com/patent/US20230053437A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 39/0011: {Cancer antigens}
- C07D 211/22: by oxygen atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 295/15: to an acyclic saturated chain
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 473/40: with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
G1 and G2 are each independently a bond, C2-C12 alkylene, or C2-C12 alkenylene;
L1 is —OC(═O)R1, —C(═O)OR′, —OC(═O)OR′, —C(═O)R1, —OR′, —S(O)xR1, —S—SR1, —C(═O)SR1, —SC(═O)R1, —NRaC(═O)R1, —C(═O)NRbRc, —NRaC(═O)NRbRc, —OC(═O)NRbRc, —NRaC(═O)OR1, —SC(═S)R1, —C(═S)SR′, —C(═S)R1, —CH(OH)R1, —P(═O)(ORb)(ORc), —(C6-C10 arylene)-R1, -(6- to 10-membered heteroarylene)-R1, or R1;
L2 is —OC(═O)R2, —C(═O)OR2, —OC(═O)OR2, —C(═O)R2, —OR2, —S(O)xR2, —S—SR2, —C(═O)SR2, —SC(═O)R2, —NRdC(═O)R2, —C(═O)NReRf, —NRdC(═O)NReRf, —OC(═O)NReRf, —NRdC(═O)OR2, —SC(═S)R2, —C(═S)SR2, —C(═S)R2, —CH(OH)R2, —P(═O)(ORe)(ORf), —(C6-C10 arylene)-R2, -(6- to 10-membered heteroarylene)-R2, or R2;
R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
Ra, Rb, Rd, and Re are each independently H, C1-C12 alkyl, or C2-C12 alkenyl;
Rc and Rf are each independently C1-C12 alkyl or C2-C12 alkenyl;
G3 and G4 are each independently C1-C12 alkylene;
L3 and L4 are each independently —OC(═O)—, —C(═O)O—, —OC(═O)O—, —C(═O)—, —O—, —S(O)x—, —S—S—, —C(═O)S—, —SC(═O)—, —NRaC(═O)—, —C(═O)NRb—, —NRaC(═O)NRO—, —OC(═O)NRb—, —NRaC(═O)O—, —SC(═S)—, —C(═S)S—, —C(═S)—, —CH(OH)—, —P(═O)(ORb)O—, —(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-;
G5 is C2-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, or C3-C8 cycloalkenylene;
R3 is —N(R4)R5 or —OR6;
R4 is hydrogen, C1-C12 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C6-C10 aryl;
R5 is C1-C12 alkyl;
or R4 and R5 together with the nitrogen to which they are attached form a cyclic moiety;
R6 is hydrogen, C1-C12 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, or C6-C10 aryl;
x is 0, 1, or 2;
n is 1, 2, or 3;
m is 1, 2, or 3; and
wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.

### Claim 2 (depends on 1)

The compound of claim 1, which is a compound of Formula (II):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein G5 is C2-C24 alkylene.

### Claim 4 (depends on 3)

The compound of claim 3, wherein G5 is C2-C6 alkylene.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1 to 4, wherein G5 is substituted with one or more oxo or C1-C6 alkyl.

### Claim 6 (depends on 1)

The compound of claim 1, which is a compound of Formula (III):
wherein s is an integer from 2 to 24,
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 7 (depends on 6)

The compound of claim 6, wherein s is an integer from 2 to 6.

### Claim 8 (depends on 7)

The compound of claim 7, wherein s is 2.

### Claim 9 (depends on 1)

The compound of claim 1, which is a compound of Formula (IV):
wherein t is an integer from 1 to 23,
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein t is an integer from 2 to 6.

### Claim 11 (depends on 10)

The compound of claim 10, wherein t is 2 or 3.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1 to 11, wherein G3 and G4 are each independently C1 or C2 alkylene.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1 to 12, wherein L3 and L4 are each independently —O—, —OC(═O)—, or —C(═O)O—.

### Claim 14 (depends on 13)

The compound of claim 13, wherein L3 and L4 are both —OC(═O)—.

### Claim 15 (depends on 13)

The compound of claim 13, wherein L3 and L4 are both —C(═O)O—.

### Claim 16 (depends on 13)

The compound of claim 13, wherein one of L3 and L4 is —O—, and the other of L3 and L4 is —OC(═O)—.

### Claim 17 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1 to 5, which is a compound of Formula (V):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 18 (depends on 6, 7, 8)

The compound of any one of claims 6 to 8, which is a compound of Formula (VI):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 19 (depends on 9, 10, 11)

The compound of any one of claims 9 to 11, which is a compound of Formula (VII):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1 to 19, wherein R3 is —N(R4)R5.

### Claim 21 (depends on 20)

The compound of claim 20, wherein R4 is C1-C12 alkyl or C3-C8 cycloalkyl.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, or cyclohexyl.

### Claim 23 (depends on 20, 21, 22)

The compound of any one of claims 20 to 22, wherein R4 is unsubstituted.

### Claim 24 (depends on 20, 21, 22)

The compound of any one of claims 20 to 22, wherein R4 is substituted with one or more hydroxyl.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The compound of any one of claims 20 to 24, wherein R5 is C1-C6 alkyl.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, or n-hexyl.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 20 to 26, wherein R5 is unsubstituted.

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 20 to 26, wherein R5 is substituted with one or more hydroxyl or —N(R10)R11, wherein:
R10 is hydrogen or C1-C6 alkyl;
R11 is C1-C6 alkyl, C3-C5 cycloalkyl, or C3-C8 cycloalkenyl;
or R10 and R11 together with the nitrogen to which they are attached form a cyclic moiety;
and R11 or the cyclic moiety is optionally substituted with one or more of hydroxyl, oxo, —NH2, —NH(C1-C6 alkyl), or —N(C1-C6 alkyl)2.

### Claim 29 (depends on 28)

The compound of claim 28, wherein R5 is substituted with

### Claim 30 (depends on 20)

The compound of claim 20, wherein R4 and R5 together with the nitrogen to which they are attached form a cyclic moiety.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the cyclic moiety is 4- to 8-membered heterocycloalkyl.

### Claim 32 (depends on 31)

The compound of claim 31, wherein the cyclic moiety is azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, azocane-1-yl, morpholinyl, 4-acetylpiperazin-1-yl.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1 to 19, wherein R3 is —OR6.

### Claim 34 (depends on 33)

The compound of claim 33, wherein R6 is hydrogen.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The compound of any one of claims 1 to 34, wherein G1 and G2 are each independently a bond or C2-C12 alkylene.

### Claim 36 (depends on 35)

The compound of claim 35, wherein G1 and G2 are each independently a bond, C5 alkylene, or C7 alkylene.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 1 to 36, wherein L1 is —OC(═O)R1, —C(═O)OR′, —C(═O)NRbRc, or R1.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1 to 37, wherein L2 is —OC(═O)R2, —C(═O)OR2, —C(═O)NReRf, or R2.

### Claim 39 (depends on 1)

The compound of claim 1, which is a compound of Formula (VIII):
or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1 to 39, wherein R1 and R2 are each independently straight C6-C24 alkyl, branched C6-C24 alkyl, or straight C6-C24 alkenyl.

### Claim 41 (depends on 40)

The compound of claim 40, wherein R1 and R2 are each independently straight C6-Cis alkyl, —R7—CH(R8)(R9), or C6-C18 alkenyl, wherein R7 is C0-C5 alkylene, and R8 and R9 are independently C2-C10 alkyl.

### Claim 42 (depends on 41)

The compound of claim 41, wherein R1 and R2 are each independently straight C7-C15 alkyl or —R7—CH(R8)(R9), wherein R7 is C0-C1 alkylene, and R8 and R9 are independently C4-C8 alkyl.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound of any one of claims 1 to 42, wherein Ra and Rd are each independently H.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1 to 43, wherein Rb, Rc, Re, and Rf are each independently n-hexyl or n-octyl.

### Claim 45

A compound in Table 1, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A composition comprising the compound of any one of claims 1 to 45, and a therapeutic or prophylactic agent.

### Claim 47 (depends on 46)

The composition of claim 46, further comprising one or more structural lipids.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the one or more structural lipids is DSPC.

### Claim 49 (depends on 47, 48)

The composition of claim 47 or 48, wherein the molar ratio of the compound to the structural lipids ranges from about 2:1 to about 8:1.

### Claim 50 (depends on 46, 47, 48, 49)

The composition of any one of claims 46 to 49, further comprising a steroid.

### Claim 51 (depends on 50)

The composition of claim 50, wherein the steroid is cholesterol.

### Claim 52 (depends on 50, 51)

The composition of claim 50 or 51, wherein the molar ratio of the compound to the steroid ranges from about 5:1 to about 1:1.

### Claim 53 (depends on 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 46 to 52, wherein the composition further comprises one or more polymer conjugated lipids.

### Claim 54 (depends on 53)

The composition of claim 53, wherein the polymer conjugated lipids is DMG-PEG2000 or DMPE-PEG2000.

### Claim 55 (depends on 53, 54)

The composition of claim 53 or 54, wherein the molar ratio of the compound to the polymer conjugated lipids ranges from about 100:1 to about 20:1.

### Claim 56 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition of any one of claims 46 to 55, wherein the therapeutic or prophylactic agent comprises at least one mRNA encoding an antigen or a fragment or epitope thereof.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the mRNA is monocistronic mRNA.

### Claim 58 (depends on 56)

The composition of claim 56, wherein the mRNA is multicistronic mRNA.

### Claim 59 (depends on 56, 57, 58)

The composition of any one of claims 56 to 58, wherein the antigen is a pathogenic antigen.

### Claim 60 (depends on 56, 57, 58)

The composition of any one of claims 56 to 58, wherein the antigen is a tumor associated antigen.

### Claim 61 (depends on 56, 57, 58, 59, 60)

The composition of any one of claims 56 to 60, wherein the mRNA comprises one or more functional nucleotide analog.

### Claim 62 (depends on 61)

The composition of claim 61, wherein the functional nucleotide analog is one or more selected from selected from pseudouridine, 1-methyl-pseudouridine and 5-methylcytosine.

### Claim 63 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The composition of any one of claims 46 to 62, wherein the composition is a nanoparticle.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A lipid nanoparticle comprising the compound of any one of claims 1 to 45, or the composition of any one of claims 46 to 62.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64)

A pharmaceutical composition comprising the compound of any one of claims 1 to 45, the composition of any one of claims 46 to 62, or the lipid nanoparticle of claim 64, and a pharmaceutically acceptable excipient or diluent.
